Advertisement
BCAX vs RCUS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAX is a Hold and RCUS is a Hold.
BCAX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BCAX turned positive on October 13, 2026. Looking at past instances where BCAX's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BCAX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 26 cases where BCAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +6.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAX advanced for three days, in 99 of 122 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
BCAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for BCAX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.369) is normal, around the industry mean (2.835). P/E Ratio (-5.466) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BCAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS sees MACD Histogram just turned negative
RCUS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 42 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The 10-day moving average for RCUS crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 217 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.070) is normal, around the industry mean (2.835). P/E Ratio (-5.614) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 60 | |
P/E GROWTH RATING 1..100 | 25 | |
SEASONALITY SCORE 1..100 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BCAX | RCUS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 83% | 4 days ago 85% |
| Stochastic ODDS (%) | 4 days ago 81% | 4 days ago 82% |
| Momentum ODDS (%) | N/A | 4 days ago 80% |
| MACD ODDS (%) | 4 days ago 89% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 80% |
| TrendMonth ODDS (%) | 4 days ago 82% | 4 days ago 77% |
| Advances ODDS (%) | 11 days ago 81% | 5 days ago 78% |
| Declines ODDS (%) | 13 days ago 89% | 7 days ago 78% |
| BollingerBands ODDS (%) | 4 days ago 79% | 4 days ago 88% |
| Aroon ODDS (%) | 4 days ago 78% | 4 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCAX’s FA Score shows that 1 FA rating(s) are green while RCUS’s FA Score has 1 green FA rating(s).
- BCAX’s FA Score: 1 green, 4 red.
- RCUS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCAX’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).
- BCAX’s TA Score: 5 bullish, 2 bearish.
- RCUS’s TA Score: 4 bullish, 5 bearish.
Price Growth
BCAX (@Biotechnology) experienced а -4.11% price change this week, while RCUS (@Biotechnology) price change was -9.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
BCAX is expected to report earnings on Nov 17, 2026.
RCUS is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PALD | 10.62 | 0.75 | +7.60% |
| Direxion Daily PANW Bear 1X ETF (PALD) | |||
| EFR | 10.18 | -0.01 | -0.10% |
| Eaton Vance Senior Floating-Rate Fund | |||
| FALN | 25.68 | -0.14 | -0.54% |
| iShares Fallen Angels USD Bond ETF (FALN) | |||
| NVBT | 40.69 | -0.43 | -1.03% |
| AllianzIM U.S. Equity Buffer10 Nov ETF (NVBT) | |||
| OGIG | 49.21 | -2.08 | -4.05% |
| ALPS O'Shares Global Internet Giants ETF (OGIG) | |||
BCAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with CLDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To BCAX | 1D Price Change % | ||
|---|---|---|---|---|
| BCAX | 100% | -4.77% | ||
| CLDX - BCAX | 46% Loosely correlated | -4.84% | ||
| RCUS - BCAX | 44% Loosely correlated | -3.07% | ||
| BCYC - BCAX | 44% Loosely correlated | -3.89% | ||
| CGON - BCAX | 43% Loosely correlated | -3.25% | ||
| RAPP - BCAX | 42% Loosely correlated | -6.76% | ||
More | ||||
RCUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To RCUS | 1D Price Change % | ||
|---|---|---|---|---|
| RCUS | 100% | -3.07% | ||
| VIR - RCUS | 49% Loosely correlated | -4.87% | ||
| XNCR - RCUS | 49% Loosely correlated | -4.79% | ||
| KURA - RCUS | 46% Loosely correlated | -6.39% | ||
| NRIX - RCUS | 44% Loosely correlated | -2.12% | ||
| BCAX - RCUS | 44% Loosely correlated | -4.77% | ||
More | ||||